Official AMFI data
Arthkar — Understand Money, Invest Smartly
Computed from real daily NAV — not projections

₹5,000 Monthly SIP in NIPPON INDIA PHARMA FUND for 10 Years

If you had started a ₹5,000/month SIP on 15 Nov 2016 and never stopped — through every crash and rally — here is exactly what happened, using NIPPON INDIA PHARMA FUND's actual NAV for all 121 installments.

You invested

₹6,05,000

121 installments

Value today

₹16,45,858

12 Nov 2026

Absolute gain

+₹10,40,858

+172%

XIRR (annualised)

19.02%

money-weighted

The journey, month by month

Portfolio value Amount invested

Worst fall on the way

-19.4%

Deepest drop from peak. This is what you had to sit through.

Corrections survived

4

Falls of 10%+ during the period. Every one recovered.

Same SIP in a fixed deposit

₹8,39,958

Modelled at historical FD rates. The fund beat FD by ₹8,05,900.

Year-by-year progress

YearInvestedValueOverall gain
Year 1 (13 Nov 2017)₹65,000₹66,318+2%
Year 2 (12 Nov 2018)₹1,25,000₹1,40,854+12.7%
Year 3 (13 Nov 2019)₹1,85,000₹1,94,938+5.4%
Year 4 (12 Nov 2020)₹2,45,000₹3,81,565+55.7%
Year 5 (12 Nov 2021)₹3,05,000₹5,77,450+89.3%
Year 6 (14 Nov 2022)₹3,65,000₹6,21,004+70.1%
Year 7 (13 Nov 2023)₹4,25,000₹8,54,314+101%
Year 8 (12 Nov 2024)₹4,85,000₹12,78,103+163.5%
Year 9 (12 Nov 2025)₹5,45,000₹13,74,318+152.2%
Year 10 (12 Nov 2026)₹6,05,000₹16,45,858+172%

Best year of the journey: Year 4 (+49.7% market move) · Toughest year: Year 3 (-2.9%)

Wealth Time Machine

Watch this exact journey as a 60-second cinematic replay

Every crash headline, every recovery — with your money in it.

Try a different amount

Try a different duration

Same SIP in other Sectoral / Thematic funds

Past performance does not guarantee future returns. This page shows the historical result of the stated SIP using NIPPON INDIA PHARMA FUND's published NAV (source: AMFI) between 15 Nov 2016 and 12 Nov 2026; it is educational research, not investment advice. FD comparison is modelled at historical average FD rates. Mutual fund investments are subject to market risks.